These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25895501)

  • 1. Structural Biology Insight for the Design of Sub-type Selective Aurora Kinase Inhibitors.
    Sarvagalla S; Coumar MS
    Curr Cancer Drug Targets; 2015; 15(5):375-93. PubMed ID: 25895501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).
    Cheung CH; Sarvagalla S; Lee JY; Huang YC; Coumar MS
    Expert Opin Ther Pat; 2014 Sep; 24(9):1021-38. PubMed ID: 24965505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.
    Noronha S; Alt LAC; Scimeca TE; Zarou O; Obrzut J; Zanotti B; Hayward EA; Pillai A; Mathur S; Rojas J; Salamah R; Chandar N; Fay MJ
    In Vitro Cell Dev Biol Anim; 2018 Jan; 54(1):71-84. PubMed ID: 29197031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAR156497, an exquisitely selective inhibitor of aurora kinases.
    Carry JC; Clerc F; Minoux H; Schio L; Mauger J; Nair A; Parmantier E; Le Moigne R; Delorme C; Nicolas JP; Krick A; Abécassis PY; Crocq-Stuerga V; Pouzieux S; Delarbre L; Maignan S; Bertrand T; Bjergarde K; Ma N; Lachaud S; Guizani H; Lebel R; Doerflinger G; Monget S; Perron S; Gasse F; Angouillant-Boniface O; Filoche-Rommé B; Murer M; Gontier S; Prévost C; Monteiro ML; Combeau C
    J Med Chem; 2015 Jan; 58(1):362-75. PubMed ID: 25369539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel inhibitors of Aurora kinases with indazole scaffold: In silico fragment-based and knowledge-based drug design.
    Chang CF; Lin WH; Ke YY; Lin YS; Wang WC; Chen CH; Kuo PC; Hsu JTA; Uang BJ; Hsieh HP
    Eur J Med Chem; 2016 Nov; 124():186-199. PubMed ID: 27573544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the Differences of Danusertib's Residence Time in Aurora Kinases A/B: Dissociation Paths and Key Residues Identified using Conventional and Enhanced Molecular Dynamics Simulations.
    Bravo-Moraga F; Bedoya M; Vergara-Jaque A; Alzate-Morales J
    J Chem Inf Model; 2024 Jun; 64(12):4759-4772. PubMed ID: 38857305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
    Payton M; Bush TL; Chung G; Ziegler B; Eden P; McElroy P; Ross S; Cee VJ; Deak HL; Hodous BL; Nguyen HN; Olivieri PR; Romero K; Schenkel LB; Bak A; Stanton M; Dussault I; Patel VF; Geuns-Meyer S; Radinsky R; Kendall RL
    Cancer Res; 2010 Dec; 70(23):9846-54. PubMed ID: 20935223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aurora isoform selectivity: design and synthesis of imidazo[4,5-b]pyridine derivatives as highly selective inhibitors of Aurora-A kinase in cells.
    Bavetsias V; Faisal A; Crumpler S; Brown N; Kosmopoulou M; Joshi A; Atrash B; Pérez-Fuertes Y; Schmitt JA; Boxall KJ; Burke R; Sun C; Avery S; Bush K; Henley A; Raynaud FI; Workman P; Bayliss R; Linardopoulos S; Blagg J
    J Med Chem; 2013 Nov; 56(22):9122-35. PubMed ID: 24195668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, quantum chemical studies and biological activity evaluation of pyrazole-benzimidazole derivatives as potent Aurora A/B kinase inhibitors.
    Zheng Y; Zheng M; Ling X; Liu Y; Xue Y; An L; Gu N; Ji M
    Bioorg Med Chem Lett; 2013 Jun; 23(12):3523-30. PubMed ID: 23664099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of BPR1K653 derivatives targeting the back pocket of Aurora kinases for selective isoform inhibition.
    Ke YY; Chang CP; Lin WH; Tsai CH; Chiu IC; Wang WP; Wang PC; Chen PY; Lin WH; Chang CF; Kuo PC; Song JS; Shih C; Hsieh HP; Chi YH
    Eur J Med Chem; 2018 May; 151():533-545. PubMed ID: 29656197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3D-QSAR and molecular docking studies on derivatives of MK-0457, GSK1070916 and SNS-314 as inhibitors against Aurora B kinase.
    Zhang B; Li Y; Zhang H; Ai C
    Int J Mol Sci; 2010 Nov; 11(11):4326-47. PubMed ID: 21151441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Dual Non-ATP Analogue Inhibitor of Aurora Kinases A and B, Derived from Resorcinol with a Mixed Mode of Inhibition.
    Karthigeyan D; Surabhi S; Mizar P; Soumik S; Banerjee A; Sinha SH; Dasgupta D; Narayana C; Kundu TK
    Chem Biol Drug Des; 2016 Jun; 87(6):958-67. PubMed ID: 26808391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
    Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
    Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line.
    Tuccilli C; Baldini E; Prinzi N; Morrone S; Sorrenti S; Filippini A; Catania A; Alessandrini S; Rendina R; Coccaro C; D'Armiento M; Ulisse S
    Endocrine; 2016 May; 52(2):287-95. PubMed ID: 26215279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design strategies, SAR, and mechanistic insight of Aurora kinase inhibitors in cancer.
    Sankhe K; Prabhu A; Khan T
    Chem Biol Drug Des; 2021 Jul; 98(1):73-93. PubMed ID: 33934503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells.
    Li JP; Yang YX; Liu QL; Zhou ZW; Pan ST; He ZX; Zhang X; Yang T; Pan SY; Duan W; He SM; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1027-62. PubMed ID: 25733818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma.
    Liu F; Wang G; Wang X; Che Z; Dong W; Guo X; Wang Z; Chen P; Hou D; Zhang Q; Zhang W; Pan Y; Yang D; Liu H
    Oncotarget; 2017 Apr; 8(17):27953-27965. PubMed ID: 28427193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a highly selective inhibitor of the Aurora kinases.
    Ferguson FM; Doctor ZM; Chaikuad A; Sim T; Kim ND; Knapp S; Gray NS
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4405-4408. PubMed ID: 28818446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells.
    Illert AL; Seitz AK; Rummelt C; Kreutmair S; Engh RA; Goodstal S; Peschel C; Duyster J; von Bubnoff N
    PLoS One; 2014; 9(11):e112318. PubMed ID: 25426931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress.
    Falchook GS; Bastida CC; Kurzrock R
    Semin Oncol; 2015 Dec; 42(6):832-48. PubMed ID: 26615129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.